4.3 Antimicrobial Dosing and Considerations in Special Populations

Antimicrobial Dosing and Considerations in Special Populations

Standard dosing recommendations derived from phase III clinical trials frequently fail in specialized patient populations characterized by extreme physiological alterations. Variations in body composition, capillary permeability, hyperdynamic organ perfusion, extracorporeal circuits, and dynamic developmental stages alter volume of distribution (Vd) and drug clearance (CL). Infectious diseases specialists must adapt dosing regimens to achieve therapeutic target attainment while mitigating toxicity across these complex cohorts.

---

Obese and Bariatric Patients

Pathophysiological and Pharmacokinetic Alterations

Obesity induces profound anatomical and physiological changes:

• Body Composition: Disproportionate expansion of adipose tissue with a moderate increase in lean body mass (~20–40% of excess weight is lean tissue).
• Extracellular Water (Vd): Total body water and extracellular fluid volume increase, but water content per kilogram of adipose tissue (~30%) is substantially lower than in lean tissue (~73%).
• Organ Perfusion and Clearance: Cardiac output, total blood volume, and splanchnic blood flow are elevated. Increased renal mass and renal plasma flow cause glomerular hyperfiltration, often elevating baseline creatinine clearance.

                               Total Body Weight (ABW)
                   ┌──────────────────────┴──────────────────────┐
                   ▼                                             ▼
        Lean Body Mass (IBW)                           Adipose Tissue Mass
       (73% Extracellular Water)                     (30% Extracellular Water)
                   │                                             │
                   ▼                                             ▼
       Hydrophilic Antimicrobials                     Lipophilic Antimicrobials
   (Beta-lactams, Aminoglycosides,                (Fluoroquinolones, Macrolides,
     Glycopeptides, Polymyxins)                    Linezolid, Tigecycline)
   Distribute minimally into adipose;             Distribute extensively into adipose;
   Use IBW or AdjBW (0.4 factor)!                 Marked increase in Vd; Use ABW!

Selection of Dosing Weight Metrics

IBW (Male) = 50 kg + 2.3 * (Height in inches - 60)
IBW (Female) = 45.5 kg + 2.3 * (Height in inches - 60)
AdjBW = IBW + 0.4 * (ABW - IBW)

Bariatric Surgery Considerations

Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy significantly reduce stomach surface area, elevate gastric pH (loss of parietal cells), bypass the duodenum and upper jejunum, and accelerate intestinal transit:

• Solubility and Dissolution: Avoid extended-release, delayed-release, or enteric-coated antimicrobial formulations (e.g., posaconazole delayed-release tablets, ciprofloxacin XR), which suffer incomplete dissolution and absorption.
• Acid-Dependent Drugs: Azole antifungals requiring an acidic gastric milieu for dissolution (ketoconazole, itraconazole capsules) exhibit severely blunted absorption. Switch to oral solutions, posaconazole delayed-release/IV, or voriconazole.

---

Critically Ill Patients: Augmented Renal Clearance and Capillary Leak

Augmented Renal Clearance (ARC)

• Definition: Enhanced renal elimination of circulating solutes, defined as an estimated or measured creatinine clearance >130 mL/min/1.73 m2 (frequently >150 mL/min). Standard serum creatinine formulas (Cockcroft-Gault, CKD-EPI) substantially underestimate renal clearance in this cohort.
• High-Risk Demographics: Young age (<50 years), polytrauma, severe thermal burns, acute pancreatitis, traumatic brain injury (TBI), sepsis without organ dysfunction, and aggressive fluid resuscitation combined with inotropic/vasopressor support.
• Pathophysiology: Massive systemic inflammatory cytokine release induces a hyperdynamic state characterized by high cardiac output, elevated renal blood flow, and glomerular hyperfiltration.
• Clinical Impact: Rapid elimination of hydrophilic, renally cleared antimicrobials (beta-lactams, vancomycin, aminoglycosides). Standard intermittent beta-lactam dosing yields undetectable serum concentrations for up to 50% of the dosing interval, directly precipitating clinical failure and emergence of resistance.

                         Systemic Inflammation / Sepsis
                                       │
         ┌─────────────────────────────┴─────────────────────────────┐
         ▼                                                           ▼
Hyperdynamic Circulation & Fluid Load                    Endothelial Glycocalyx Disruption
(High Cardiac Output & Renal Perfusion)                  (Vascular Hyperpermeability)
         │                                                           │
         ▼                                                           ▼
Augmented Renal Clearance (ARC)                          Capillary Leak & Third-Spacing
(CrCl > 130-150 mL/min)                                  (Expansion of Extracellular Water)
         │                                                           │
         ▼                                                           ▼
Rapid Beta-Lactam Elimination                            Massive Increase in Vd for Hydrophilic Drugs
(Subtherapeutic Troughs)                                 (Subtherapeutic Initial Peak Concentrations)
         │                                                           │
         └─────────────────────────────┬─────────────────────────────┘
                                       ▼
             Management: Full Weight-Based Loading Dose + High Doses
             administered as Extended or Continuous 24-Hour Infusions

• Overcoming ARC:
  1. Shorten the dosing interval (e.g., piperacillin-tazobactam 4.5 g IV every 6 hours).
  2. Maximize the infusion duration (extended 3- to 4-hour infusions or continuous 24-hour infusions).
  3. Escalate daily doses guided by therapeutic drug monitoring (TDM).

Capillary Leak Syndrome and Third-Spacing

Endothelial glycocalyx disruption in severe sepsis permits rapid extravasation of albumin and plasma fluid into the interstitial space (producing generalized anasarca, pleural effusions, and ascites). This dramatically expands the volume of distribution (Vd) for hydrophilic antimicrobials, causing subtherapeutic initial serum concentrations.

Kinetic GFR in Sepsis-Induced Acute Kidney Injury

Serum creatinine is an insensitive, lagging biomarker that delays recognition of acute changes in filtration by 24 to 48 hours. In evolving acute kidney injury (AKI), mathematical equations overestimate the true GFR; in recovering AKI, they underestimate true GFR. Clinicians should evaluate urine output trajectory and use kinetic GFR calculations or therapeutic drug monitoring rather than relying solely on static serum creatinine.

---

Renal Replacement Therapies (CRRT, IHD, SLED)

Continuous Renal Replacement Therapy (CRRT)

CRRT modalities—Continuous Veno-Venous Hemofiltration (CVVH; convective clearance), Continuous Veno-Venous Hemodialysis (CVVHD; diffusive clearance), and Continuous Veno-Venous Hemodiafiltration (CVVHDF; combined convective and diffusive clearance)—run continuously in hemodynamically unstable ICU patients.

              Determinants of Antimicrobial Removal in CRRT
                                   │
       ┌───────────────────────────┼───────────────────────────┐
       ▼                           ▼                           ▼
Effluent Flow Rate         Protein Binding (fu)       Volume of Distribution
Qeffluent = Quf + Qd       Sc ≈ fu = 1 - Bound        Only circulating drug in
Directly proportional      Only free unbound drug     plasma is cleared;
to drug clearance          passes through filter      Vd > 1.5-2 L/kg: minimal
(20-35 mL/kg/h)            membrane!                  dialytic clearance

• Mechanisms of Filter Clearance:
  • Convection (Hemofiltration): Solutes are dragged across a semipermeable membrane alongside ultrafiltered plasma water. The sieving coefficient (Sc) reflects membrane permeability:

Sc = C_ultrafiltrate / C_plasma ≈ fu = 1 - Protein Binding

• Diffusion (Hemodialysis): Solutes move down a concentration gradient into counter-current dialysate fluid, governed by the saturation coefficient (Sd ≈ fu).
• Effluent Flow Rate (Qeffluent): The primary operational determinant of clearance (CL_CRRT = Qeffluent * Sc). Contemporary standard effluent rates range from 20 to 35 mL/kg/h.
• Molecular Determinants of Drug Clearance:
  1. Protein Binding: Only free, unbound drug (fu) crosses the hemofilter. Highly protein-bound drugs (ceftriaxone 90–95%, ertapenem 95%, daptomycin 90–93%) are minimally cleared by CRRT. Hydrophilic agents with low protein binding (meropenem 2%, cefepime 20%, vancomycin 30–50%, aminoglycosides <10%) are cleared extensively.
  2. Molecular Weight: Standard high-flux polysulfone filters have pore cutoffs of 20,000 to 30,000 Da. Virtually all antimicrobials (MW 200–1,500 Da) pass freely unless bound to albumin (66,000 Da).
  3. Volume of Distribution (Vd): Drugs with large Vd (>1.5–2 L/kg, e.g., azithromycin, fluoroquinolones, linezolid) reside primarily in tissues; extracorporeal clearance has negligible impact on total body elimination.
• Dosing Rule in CRRT: Because CRRT operates 24 hours daily with high effluent flows, antimicrobial underdosing is the predominant clinical error. For hydrophilic beta-lactams, dose as if the patient has a baseline creatinine clearance of 30 to 50 mL/min:
  • Meropenem: 1 g IV every 8 to 12 hours (extended infusion).
  • Cefepime: 2 g IV every 8 to 12 hours (extended infusion).
  • Piperacillin-Tazobactam: 3.375 g to 4.5 g IV every 8 hours (or 13.5 g/24h continuous infusion).
  • Vancomycin: 25 to 35 mg/kg loading dose, then 15 to 20 mg/kg every 24 hours, monitored by AUC.

Intermittent Hemodialysis (IHD)

IHD runs for 3 to 4 hours per session, 3 times weekly, utilizing high-efficiency blood flow (300–500 mL/min) and dialysate flow (500–800 mL/min). High-flux dialyzers remove 30% to 50% of dialyzable antimicrobials during a single treatment.

• Administration Timing: Antimicrobial doses must always be administered immediately following the hemodialysis session (post-HD). Dosing prior to dialysis results in premature drug extraction into dialysate and profound subtherapeutic exposure.
• Supplemental Dosing: If a dose must be administered prior to dialysis for clinical stabilization, a supplemental replacement dose (typically 30–50% of the maintenance dose) is required post-HD.
• Specific Regimens:
  • Cefepime: 1 g to 2 g IV post-HD (caution: high risk of neurotoxicity if unadjusted).
  • Meropenem: 500 mg to 1 g IV post-HD.
  • Vancomycin: Weight-based maintenance (500–1,000 mg) infused post-HD, targeting pre-dialysis serum concentrations of 15 to 20 mcg/mL.

Sustained Low-Efficiency Dialysis (SLED)

SLED is a hybrid modality operating over 6 to 12 hours at intermediate blood (150–250 mL/min) and dialysate (100–300 mL/min) flows. Clearance falls between IHD and CRRT. Administer antimicrobials either during the final 1 to 2 hours of the SLED session or immediately upon its completion.

---

Pregnancy and Lactation

Maternal Physiological Adaptations

1. Expanded Plasma Volume: Maternal plasma volume increases by ~50%, and total body water expands, increasing the Vd of hydrophilic antimicrobials.
2. Enhanced Glomerular Filtration: Renal blood flow and GFR increase by 40–50% starting in the first trimester, accelerating the clearance of renally eliminated drugs.
3. Hypoalbuminemia: Dilutional reduction in serum albumin increases the free (unbound) fraction of protein-bound drugs.
4. Hepatic Enzyme Alterations: Estrogen and progesterone induce CYP3A4, CYP2D6, and UGT glucuronidation while inhibiting CYP1A2.
5. Dosing Consequence: Pregnant women frequently exhibit lower serum concentrations of beta-lactams and require higher doses or shorter dosing intervals (e.g., ampicillin 2 g IV every 4 hours for GBS prophylaxis or listeriosis).

Pregnancy and Lactation Labeling Rule (PLLR)

The FDA replaced the legacy letter categories (A, B, C, D, X) with narrative risk summaries under three subsections:

• 8.1 Pregnancy: Details fetal risk, clinical considerations (disease-associated maternal/fetal risk, dose adjustments), and human pregnancy exposure registry data.
• 8.2 Lactation: Outlines drug presence in human milk, effects on the breastfed infant, and impact on milk production.
• 8.3 Females and Males of Reproductive Potential: Evaluates need for pregnancy testing, contraception requirements, and potential effects on fertility.

Antimicrobial Teratogenicity and Safety Spectrum

Lactation and Infant Exposure

Excretion into breast milk is governed by maternal serum concentration, low molecular weight, lipophilicity, low protein binding, and milk pH (human milk is slightly acidic, pH ~7.0–7.2, favoring ion trapping of basic drugs like macrolides). The Relative Infant Dose (RID) is calculated as:

RID = (Infant Dose [mg/kg/day] / Maternal Dose [mg/kg/day]) * 100

An RID < 10% is considered clinically safe. Penicillins, cephalosporins, macrolides, and vancomycin exhibit an RID < 1–2% and are compatible with breastfeeding. Infant monitoring is focused on alteration of bowel flora (loose stools, diarrhea), oral candidiasis (thrush), and allergic sensitization.

---

Geriatric and Pediatric Considerations

Geriatric Pharmacotherapy

1. Age-Related Decline in Renal Function: Nephron mass decreases by 30% to 40% between ages 30 and 80, with GFR declining at an average rate of 1 mL/min/year after age 40.
2. The Sarcopenia Diagnostic Pitfall: Sarcopenia (loss of skeletal muscle mass) severely reduces endogenous creatinine generation. Consequently, a frail, 85-year-old bedbound patient with an apparently "normal" serum creatinine of 0.8 mg/dL may actually have a true creatinine clearance <30 mL/min. Dosing based on serum creatinine without formal Cockcroft-Gault calculation leads to massive drug accumulation and severe toxicity.
3. Body Composition: Total body water decreases (reducing Vd for hydrophilic drugs and increasing peak serum levels), whereas body fat percentage increases (expanding Vd and prolonging the elimination half-life of lipophilic drugs).
4. Neurotoxicity Vulnerabilities:
   • Cefepime Neurotoxicity: Manifests as confusion, myoclonus, encephalopathy, and non-convulsive status epilepticus, occurring predominantly in elderly patients with unrecognized or unadjusted renal impairment.
   • Fluoroquinolones: Elderly patients face heightened risks of severe central nervous system toxicities (toxic delirium, hallucinations), peripheral neuropathy, tendonitis/Achilles tendon rupture, and QTc prolongation.

Pediatric Pharmacotherapy

                    Dynamic Pediatric Developmental Milestones
                                       │
       ┌───────────────────────────────┴───────────────────────────────┐
       ▼                                                               ▼
Preterm & Term Neonates                                Older Infants & Children
- Extracellular water = 75-80% of body weight          - Maturation of renal filtration & tubular secretion
- Immature hepatic glucuronidation (UGT)               - Enhanced drug clearance per kilogram body weight
- Reduced GFR and tubular secretion                    - Shorter beta-lactam elimination half-lives
- Lower protein binding (higher free fraction)         - Often require higher mg/kg doses or shorter intervals!

• Neonatal Ceftriaxone Contraindications (≤ 28 Days of Life): Ceftriaxone is strictly contraindicated in neonates due to two lethal mechanisms:
  1. Bilirubin Displacement: Ceftriaxone has high protein binding (90–95%) and displaces unconjugated bilirubin from serum albumin binding sites. Free bilirubin crosses the immature blood-brain barrier, precipitating in basal ganglia and brainstem nuclei to produce kernicterus (bilirubin encephalopathy, choreoathetosis, sensorineural hearing loss, death).
  2. Calcium Precipitation: Ceftriaxone binds calcium to form insoluble crystalline calcium-ceftriaxone precipitates that lodge in pulmonary and renal microvasculature, causing fatal embolization. Co-administration of ceftriaxone with intravenous calcium-containing solutions (e.g., Ringer's lactate, parenteral nutrition) is strictly contraindicated in neonates, even via separate infusion lines.
  • The Pediatric Solution: Cefotaxime is the preferred third-generation cephalosporin for neonates because it does not displace bilirubin and does not precipitate with intravenous calcium.
• Chloramphenicol and Gray Baby Syndrome: Neonates lack mature hepatic UDP-glucuronosyltransferase enzymes. Administration of chloramphenicol leads to toxic drug accumulation, myocardial depression, flaccidity, ashen gray cyanosis, cardiovascular collapse, and death.
• Contemporary Doxycycline Safety Update in Pediatrics: Historical literature cautioned against tetracyclines in children <8 years due to tooth staining and enamel hypoplasia. However, contemporary guidelines from the American Academy of Pediatrics (AAP) and the CDC confirm that short courses of doxycycline (≤ 21 days) do NOT cause visible dental staining or enamel defects, because doxycycline binds calcium with significantly lower affinity than older tetracyclines. Doxycycline is the absolute drug of choice for suspected Rocky Mountain spotted fever (RMSF), Lyme disease, and ehrlichiosis/anaplasmosis in pediatric patients of ANY age. Delaying doxycycline therapy in suspected RMSF while seeking alternative agents dramatically increases pediatric mortality.